CytoDyn Inc. (CYDY)
CytoDyn Inc.
1111 Main Street
Suite 660
Vancouver, WA 98660
United States
360 980 8524
https://www.cytodyn.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 12
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Cyrus Arman M.B.A., Ph.D. | Senior Vice President of Business Operations | 451.17k | N/D | 1982 |
| Dr. Jacob P. Lalezari M.D. | CEO & Member of Scientific Advisory Board | N/D | N/D | 1960 |
| Mr. Mitchell Cohen | Interim Chief Financial Officer | N/D | N/D | 1957 |
| Mr. Tyler Blok | Executive Vice President of Legal Affairs & Secretary | N/D | N/D | 1988 |
| Dr. Scott Hansen Ph.D. | Head of Research & Basic Science | N/D | N/D | N/D |
| Mr. Joseph Meidling | Executive Director of Clinical Operations | N/D | N/D | N/D |
| Ms. Cristina De Leon | Investors | N/D | N/D | N/D |
Descripción
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Gestión corporativa
La calificación ISS Governance QuickScore de CytoDyn Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
